Gene therapy for Dravet may need to be lifelong treatment, study finds
New treatment approaches, such as gene therapies, that aim to restore the activity of SCN1A, the gene often defective in Dravet syndrome patients, must remain active throughout adulthood to adequately maintain brain function, a lab study suggests. Using a Dravet mouse model, the work showed that activating a…